Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance (NCT02673749) | Clinical Trial Compass
CompletedPhase 2/3
Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance
United States377 participantsStarted 2016-02
Plain-language summary
RP-G28 is being investigated for treatment of moderate to severe lactose intolerance and its potential to improve the tolerance of lactose (dairy products).
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion/Exclusion Criteria:
* Female subjects must be non pregnant, and non lactating. Females of childbearing potential must use adequate birth control during study participation
* Medical history of intolerance to milk and other dairy products, and/or confirmed physician diagnosis of lactose intolerance.
* Must be free from any disorder known to be associated with gastrointestinal disease: irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), Celiac disease, diverticulitis, chronic constipation, chronic pancreatitis, pancreatic insufficiency, symptomatic biliary disease, small intestine bacterial overgrowth syndrome (SIBO), active gastric or duodenal ulcers, or history of severe ulcers.
* Must be nicotine free.